Twist Bioscience Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TWST research report →
About the company
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage.
- CEO
- Emily Marine Leproust
- IPO
- 2018
- Employees
- 923
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $6.18B
- P/E
- -75.18
- P/S
- 15.09
- P/B
- 13.46
- EV/EBITDA
- -109.21
- Div Yield
- 0.00%
- Gross Margin
- 52.07%
- Op Margin
- -33.90%
- Net Margin
- -19.85%
- ROE
- -17.46%
- ROIC
- -24.50%
- Revenue
- $376.57M · 20.32%
- Net Income
- $-77,670,000 · 62.79%
- EPS
- $-1.30 · 63.89%
- Op Income
- $-136,259,000
- FCF YoY
- -9.34%
- 52W High
- $105.47
- 52W Low
- $23.30
- 50D MA
- $69.62
- 200D MA
- $46.34
- Beta
- 2.12
- Avg Volume
- 1.72M
Get TickerSpark's AI analysis on TWST
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 26 | Leproust Emily M. | sell | 18,880 |
| Jun 24, 26 | Cho Dennis | sell | 14,205 |
| Jun 22, 26 | Green Paula | sell | 291 |
| Jun 22, 26 | Cho Dennis | sell | 346 |
| Jun 22, 26 | Leproust Emily M. | sell | 1,688 |
| Jun 15, 26 | Green Paula | other | 26,137 |
| Jun 15, 26 | Green Paula | sell | 24,109 |
| Jun 15, 26 | Green Paula | sell | 2,028 |
| Jun 15, 26 | Green Paula | other | 26,137 |
| Jun 8, 26 | Cho Dennis | sell | 402 |
Our TWST coverage
Recent articles, reports, and earnings notes.
Twist Bioscience (TWST): Margin Gains, But Valuation Is Rich
Twist Bioscience is scaling revenue, expanding gross margin, and gaining traction in AI-enabled discovery, but the stock already prices in much of the progress. Our view is Hold as the company works toward profitability.
Twist Bioscience Corporation (TWST) drops after deep earnings miss
Twist Bioscience Corporation (TWST) drops despite revenue growth and raised guidance, as a wider-than-expected EPS loss overshadowed strong segment momentum, margin improvement, and continued sequential sales gains. This deep-dive breaks down the earnings miss, operating trends, and why investors focused on profitability over the top-line beat.
Twist Bioscience Corporation (TWST) drops on earnings misses
Twist Bioscience Corporation (TWST) drops 5.5% after reporting earnings misses, as investors react to weaker-than-expected results and reassess the stock's near-term outlook.
Want a deeper read on TWST?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.